[go: up one dir, main page]

CA2370099A1 - Peptides modifies bh3 - Google Patents

Peptides modifies bh3 Download PDF

Info

Publication number
CA2370099A1
CA2370099A1 CA002370099A CA2370099A CA2370099A1 CA 2370099 A1 CA2370099 A1 CA 2370099A1 CA 002370099 A CA002370099 A CA 002370099A CA 2370099 A CA2370099 A CA 2370099A CA 2370099 A1 CA2370099 A1 CA 2370099A1
Authority
CA
Canada
Prior art keywords
leu
ser
amino acid
ile
asn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002370099A
Other languages
English (en)
Inventor
Barry A. Morgan
Gregoire Prevost
Thomas G. Cotter
Nicola Finnegan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS filed Critical Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Publication of CA2370099A1 publication Critical patent/CA2370099A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention se rapporte à un peptide représenté par la formule (I), définie dans la description associée, ou à un sel pharmaceutiquement acceptable de ce peptide, à des compositions pharmaceutiques comportant ledit peptide de formule (I) et à l'utilisation de ces compositions pour restaurer l'apoptose dans des cellules tumorales humaines. Le composé de formule (I) de la présente invention est R-A?1¿-A?2¿-A?3¿-A?4¿-A?5¿-A?6¿-A?7¿-A?8¿-A?9¿-A?10¿-A?11¿-A?12¿-A?13¿-A?14¿-A?15¿-NHR?1¿ ou un sel pharmaceutiquement acceptable de ce composé, où R est acyle (C¿1?-C¿5?); A?1¿ est absent ou un acide aminé aliphatique; A?2¿ est absent ou est sélectionné dans le groupe constitué par Gly, Ala, Ser, Thr et Asn; A?3¿ et A?4¿ sont chacun absents ou sont chacun un acide aminé codé; A?5¿ est un acide aminé aliphatique; A?6¿ est Ala ou un acide aminé basique; A?7¿ est sélectionné dans le groupe constitué par Ile, Leu, Val, Ser, Thr, Lys et Arg; A?8¿ est un acide aminé aliphatique; A?9¿ est Gly; A?10¿ et A?11¿ sont chacun indépendamment Asp ou Glu; A?12¿ est un acide aminé aliphatique Ile, Leu Met et Val; A?13¿ est Asp, Glu ou Asn; A?14¿ et A?15¿ sont chacun indépendamment absent ou sélectionné dans le groupe constitué par Ile, Leu, Val, Met, Ser, Thr, Asn, Lys et Arg; et R?1¿ est alkyle (C¿1?-C¿5?).
CA002370099A 1999-06-25 2000-06-23 Peptides modifies bh3 Abandoned CA2370099A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14102799P 1999-06-25 1999-06-25
US60/141,027 1999-06-25
PCT/US2000/017283 WO2001000670A1 (fr) 1999-06-25 2000-06-23 Peptides modifies bh3

Publications (1)

Publication Number Publication Date
CA2370099A1 true CA2370099A1 (fr) 2001-01-04

Family

ID=22493839

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002370099A Abandoned CA2370099A1 (fr) 1999-06-25 2000-06-23 Peptides modifies bh3

Country Status (6)

Country Link
EP (1) EP1189939A1 (fr)
JP (1) JP2003507471A (fr)
AU (1) AU5761200A (fr)
CA (1) CA2370099A1 (fr)
NO (1) NO20016188L (fr)
WO (1) WO2001000670A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100685345B1 (ko) 2004-03-27 2007-02-22 학교법인조선대학교 세포사 유도 펩타이드

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656725A (en) * 1995-05-12 1997-08-12 Apoptosis Technology, Inc. Peptides and compositions which modulate apoptosis
AU9402898A (en) * 1997-09-26 1999-04-23 Washington University Cell death agonists

Also Published As

Publication number Publication date
JP2003507471A (ja) 2003-02-25
EP1189939A1 (fr) 2002-03-27
NO20016188D0 (no) 2001-12-18
NO20016188L (no) 2002-02-21
AU5761200A (en) 2001-01-31
WO2001000670A1 (fr) 2001-01-04

Similar Documents

Publication Publication Date Title
KR102566709B1 (ko) 프로그램 된 세포사멸을 유도하는 cd47의 효능제 및 이의 프로그램 된 세포사멸 결함과 관련된 질병 치료에의 용도
EP2994533B1 (fr) Procédés et compositions de traitement du cancer
KR102017645B1 (ko) 세포자멸사의 억제제 및 이의 용도
EP1758932A2 (fr) Derives de metastine et leur utilisation
WO1998017682A1 (fr) Mutants a substitution serine de regulateur de mort de cellules associees a bcl-xl/bcl-2
US6911426B2 (en) Methods and compositions for derepression of IAP-inhibited caspase
US6831155B2 (en) Inhibition of p53 degradation
WO1998016641A1 (fr) Isolation et procede d'utilisation de la proteine frzb induisant la croissance de tissus
KR101368607B1 (ko) 메타스틴 유도체 및 그의 용도
EP1458754B1 (fr) Nouvelles proteines associees a la mort, et mecanismes d'action de thap1 et para4 dans la maitrise de l'apoptose
US6570002B1 (en) Inhibitor of programmed cell death
Liu et al. Synthetic peptides and non-peptidic molecules as probes of structure and function of Bcl-2 family proteins and modulators of apoptosis
JP3906078B2 (ja) Ｂｈ４融合ポリペプチド
CA2370099A1 (fr) Peptides modifies bh3
JP2003502440A (ja) ペプチドの使用
WO1998009643A1 (fr) Modulation de l'apoptoste par phophorylation de la serine du regulateur de mort cellulaire associe a bcl-xl/bcl-2
JP2001502897A (ja) 細胞毒性ペプチド
US20240016943A1 (en) Synthetic dna binding domains and uses thereof
US20100317598A1 (en) Isolated BRCA1 Peptides and Method of Use
US20060198832A1 (en) Peptide drugs for chronic lymphocytic leukemia (CLL) and other cancers
KR20230006581A (ko) 고형암의 치료에 사용하기 위한 pcna 상호작용 모티프를 함유하는 펩티드
Strohecker Caspase cleavage of HER-2/neu releases a BH3-like cell death effector
KR20070031949A (ko) 메타스틴 유도체 및 이의 용도

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead